Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED) - 12/07/23

Atsushi Tanaka ^⁎

 Department of Cardiovascular Medicine, Saga University, Saga, Japan 

^⁎Correspondence authors at: Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.Department of Cardiovascular MedicineSaga University5-1-1 NabeshimaSaga849-8501Japan

Yosuke Okada, Keiichi Torimoto

 First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 

Nozomu Kamei

 Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan 

Hiroyuki Hirai

 Department of Internal Medicine, Shirakawa Kosei General Hospital, Shirakawa, Japan 

Teruyuki Kono

 Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan 

Kazuhiro Sugimoto

 Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Japan 

Hiroki Teragawa

 Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan 

Isao Taguchi

 Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan 

Tatsuya Maruhashi

 Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan 

Satomi Sonoda, Akira Kurozumi

 First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 

Saori Inagaki

 Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan 

Chikage Oshita

 Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan 

Itaru Hisauchi

 Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan 

Kanae Takahashi

 Department of Biostatistics, Hyogo Medical University, Nishinomiya, Japan 

Yukihito Higashi

 Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan 

Michio Shimabukuro

 Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan 

Koichi Node ^⁎
on behalf of the

PROCEED Trial Investigators

 Department of Cardiovascular Medicine, Saga University, Saga, Japan 

Le texte complet de cet article est disponible en PDF.